50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,626.27 (-2.49%)
DOW   29,119.27 (-1.90%)
QQQ   270.68 (-3.31%)
AAPL   142.92 (-4.62%)
MSFT   234.40 (-2.77%)
META   135.63 (-4.22%)
GOOGL   96.33 (-3.72%)
AMZN   113.70 (-3.65%)
TSLA   271.35 (-5.72%)
NVDA   121.10 (-4.92%)
NIO   16.01 (-7.62%)
BABA   77.28 (-4.58%)
AMD   64.84 (-5.15%)
T   15.56 (-1.71%)
MU   49.40 (-3.14%)
CGC   2.82 (-7.24%)
F   11.42 (-6.24%)
GE   62.34 (-3.29%)
DIS   97.03 (-2.38%)
AMC   7.14 (-6.91%)
PYPL   88.86 (-2.48%)
PFE   44.04 (-0.88%)
NFLX   240.53 (-1.90%)
S&P 500   3,626.27 (-2.49%)
DOW   29,119.27 (-1.90%)
QQQ   270.68 (-3.31%)
AAPL   142.92 (-4.62%)
MSFT   234.40 (-2.77%)
META   135.63 (-4.22%)
GOOGL   96.33 (-3.72%)
AMZN   113.70 (-3.65%)
TSLA   271.35 (-5.72%)
NVDA   121.10 (-4.92%)
NIO   16.01 (-7.62%)
BABA   77.28 (-4.58%)
AMD   64.84 (-5.15%)
T   15.56 (-1.71%)
MU   49.40 (-3.14%)
CGC   2.82 (-7.24%)
F   11.42 (-6.24%)
GE   62.34 (-3.29%)
DIS   97.03 (-2.38%)
AMC   7.14 (-6.91%)
PYPL   88.86 (-2.48%)
PFE   44.04 (-0.88%)
NFLX   240.53 (-1.90%)
S&P 500   3,626.27 (-2.49%)
DOW   29,119.27 (-1.90%)
QQQ   270.68 (-3.31%)
AAPL   142.92 (-4.62%)
MSFT   234.40 (-2.77%)
META   135.63 (-4.22%)
GOOGL   96.33 (-3.72%)
AMZN   113.70 (-3.65%)
TSLA   271.35 (-5.72%)
NVDA   121.10 (-4.92%)
NIO   16.01 (-7.62%)
BABA   77.28 (-4.58%)
AMD   64.84 (-5.15%)
T   15.56 (-1.71%)
MU   49.40 (-3.14%)
CGC   2.82 (-7.24%)
F   11.42 (-6.24%)
GE   62.34 (-3.29%)
DIS   97.03 (-2.38%)
AMC   7.14 (-6.91%)
PYPL   88.86 (-2.48%)
PFE   44.04 (-0.88%)
NFLX   240.53 (-1.90%)
S&P 500   3,626.27 (-2.49%)
DOW   29,119.27 (-1.90%)
QQQ   270.68 (-3.31%)
AAPL   142.92 (-4.62%)
MSFT   234.40 (-2.77%)
META   135.63 (-4.22%)
GOOGL   96.33 (-3.72%)
AMZN   113.70 (-3.65%)
TSLA   271.35 (-5.72%)
NVDA   121.10 (-4.92%)
NIO   16.01 (-7.62%)
BABA   77.28 (-4.58%)
AMD   64.84 (-5.15%)
T   15.56 (-1.71%)
MU   49.40 (-3.14%)
CGC   2.82 (-7.24%)
F   11.42 (-6.24%)
GE   62.34 (-3.29%)
DIS   97.03 (-2.38%)
AMC   7.14 (-6.91%)
PYPL   88.86 (-2.48%)
PFE   44.04 (-0.88%)
NFLX   240.53 (-1.90%)
NASDAQ:ITRM

Iterum Therapeutics - ITRM Stock Forecast, Price & News

$1.83
+0.04 (+2.23%)
(As of 09/29/2022 09:52 AM ET)
Add
Compare
Today's Range
$1.82
$1.83
50-Day Range
$1.59
$43.50
52-Week Range
$1.58
$11.25
Volume
300 shs
Average Volume
98,373 shs
Market Capitalization
$22.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Iterum Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.11mentions of Iterum Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$156,000 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.15) to ($4.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

770th out of 1,096 stocks

Pharmaceutical Preparations Industry

373rd out of 548 stocks

ITRM stock logo

About Iterum Therapeutics (NASDAQ:ITRM) Stock

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITRM Stock News Headlines

Iterum Therapeutics Shares Are Surging - Read Why
Iterum Therapeutics plc Ordinary Share (ITRM)
See More Headlines
Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITRM Company Calendar

Last Earnings
8/12/2022
Today
9/29/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITRM
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$-91,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$40,000.00
Book Value
$4.12 per share

Miscellaneous

Free Float
11,798,000
Market Cap
$22.40 million
Optionable
Not Optionable
Beta
1.26

Key Executives

  • Mr. Corey N. Fishman (Age 57)
    Pres, CEO & Director
    Comp: $939.26k
  • Ms. Judith M. Matthews (Age 52)
    Chief Financial Officer
    Comp: $533.85k
  • Dr. Michael W. Dunne M.D. (Age 62)
    Strategic Advisor & Director
    Comp: $377.8k
  • Dr. Sailaja Puttagunta M.D. (Age 53)
    Chief Medical Officer
    Comp: $125.79k
  • Mr. Tom Loughman Ph.D.
    Sr. VP of Technical Operations
  • Ms. Louise Barrett
    Sr. VP of Legal Affairs & Sec.
  • Dr. Steven I. Aronin M.D.
    Sr. VP & Head of Clinical Devel.













ITRM Stock - Frequently Asked Questions

Should I buy or sell Iterum Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ITRM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ITRM, but not buy additional shares or sell existing shares.
View ITRM analyst ratings
or view top-rated stocks.

How have ITRM shares performed in 2022?

Iterum Therapeutics' stock was trading at $5.88 at the beginning of 2022. Since then, ITRM stock has decreased by 69.6% and is now trading at $1.79.
View the best growth stocks for 2022 here
.

When is Iterum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our ITRM earnings forecast
.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics plc (NASDAQ:ITRM) posted its quarterly earnings results on Friday, August, 12th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.45.

When did Iterum Therapeutics' stock split?

Iterum Therapeutics shares reverse split on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), Ocugen (OCGN).

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

How do I buy shares of Iterum Therapeutics?

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $1.79.

How much money does Iterum Therapeutics make?

Iterum Therapeutics (NASDAQ:ITRM) has a market capitalization of $21.91 million and generates $40,000.00 in revenue each year. The company earns $-91,560,000.00 in net income (profit) each year or ($0.8996) on an earnings per share basis.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The official website for the company is www.iterumtx.com. The company can be reached via phone at (531) 903-8920 or via email at ir@iterumtx.com.

This page (NASDAQ:ITRM) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.